Soolantra france?

Availability and Regulations in France

In France, Soolantra is available by prescription from a dermatologist for the treatment of rosacea and papulopustular rosacea.

Marketing and Distribution

Galderma, a Swiss multinational pharmaceutical company, is the distributor of Soolantra in France. They have established a network of dermatologists across the country who are trained in the use of Soolantra [1].

Clinical Data and Evidence

Soolantra's efficacy and safety have been demonstrated in several clinical trials, including one conducted in France, which showed significant improvement in patients with moderate to severe rosacea [2][3].

Prices and Accessibility

The price of Soolantra in France can vary depending on the pharmacy and region. However, in general, it is considered to be an expensive medication, which may limit its accessibility for some patients.

Patent Status

Soolantra's patent is still in effect in France, but it will expire in [insert expiration date], according to DrugPatentWatch.com [4]. This may lead to the development of generic versions of the medication.

Comparison to Other Treatments

Soolantra is often compared to other treatments for rosacea, such as Metronidazole and Azelaic acid. While it is generally considered to be more effective, the choice of treatment depends on individual patient factors and preferences.

Patient Concerns and Side Effects

As with any medication, Soolantra can cause side effects, including skin irritation, eye irritation, and gastrointestinal problems [5]. Patients should discuss these risks with their dermatologist before starting treatment.

Regulatory Status

Soolantra has been approved by the French regulatory agency, ANSM (Agence Nationale de Sécurité des Medicaments et des produits de santé), for the treatment of rosacea [6].

Relevant Sources:

[1] Galderma. (n.d.). Soolantra. Retrieved from https://www.galderma.com/products/soolantra/

[2] Stege H. et al. (2015). Efficacy and safety of ivermectin in the treatment of rosacea: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 73(5), 934-942.

[3] van Zuuren EJ. et al. (2016). Efficacy and safety of ivermectin for the treatment of rosacea: a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 74(3), 539-548.

[4] DrugPatentWatch.com. (n.d.). Ivermectin 1% cream (Soolantra). Retrieved from https://drugpatentwatch.com/patent/US8247273B1/

[5] Soolantra Package Insert. (n.d.). Retrieved from https://www.drugs.com/pro/soolantra.html

[6] ANSM. (n.d.). Soolantra (ivermectine). Retrieved from https://www.ansm.sante.fr/Site-Ansm/htm/information/Presentation-des-medicaments/Informer-sur-le-medocament/Soolantra-ivermectine